Navigation Links
China Cord Blood Corporation Received AABB Accreditation
Date:4/2/2013

HONG KONG, April 2, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced that the cord blood bank operated by its Beijing subsidiary has been granted the AABB Accreditation, as a certification of its quality excellence of providing cord blood processing and storage services.

As an indication of established quality system and proven track record, the AABB conducts an Accreditation Program which follows an intensive on-site assessment by specially trained AABB assessors and establishes that the level of technical and administrative performance within the facility meets or exceeds the standards set by AABB. 

"We are very pleased to receive the AABB Accreditation," said Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.  "It demonstrates our consistent commitment of advanced learning, continuous improvement, and innovation to sustain top level of quality and safety.  Today, our effort has been recognized and validated."

AABB's Accreditation Program contributes to the quality and safety of collecting, processing, testing, distributing and administering blood and cellular therapy products, as well as assessing the quality and operational systems in place within a facility.  

Ms. Zheng concluded, "Voluntarily participating in AABB's Accreditation Program signals our commitment to achieve quality and our dedication to offer excellent quality assurance to the society that we serve."

About AABB

Established in 1947, AABB is an international, not-for-profit association dedicated the advancement of science and the practice of blood centers, transfusion medicine and related biological therapies.  The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries. For more information, please visit www.aabb.org.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company's website at http://www.chinacordbloodcorp.com.    

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com  

ICR, Inc.
Mr. Bill Zima
Tel: (+86) 10-6583-7511 or (646) 405-5185
Email: bill.zima@icrinc.com


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Diagnostic Reagent Industry Report, 2012-2014
2. Research on China's FISH Probe (Fluorescent in Situ Hybridization Probe) Industry, 2013-2017
3. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
4. China Probiotics Market 2012-2016
5. China Market Data: Acrylonitrile, Phytol and Branched Chain Amino Acids Analysis in New Research Reports at RnRMarketResearch.com
6. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
7. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
8. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
9. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
10. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
11. China Cord Blood Corporation to Further Consolidate its Corporate Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... ... of biologics. To acquire information on the desired increase and/or decrease in antibody-dependent ... industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this ...
(Date:3/22/2017)... (PRWEB) , ... March 21, ... ... ( WMFTG ) has unveiled its innovative Quantum peristaltic pump with patented ... innovation, Quantum sets the new standard for high-pressure feed pumps in SU ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... Lebovits , Chief Executive Officer, will provide an update ... Associates 2 nd Annual Neuroscience Biopartnering and Investment ... the New York Academy of Sciences. ...
Breaking Biology Technology:
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):